BioCentury
ARTICLE | Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

January 19, 2019 12:30 AM UTC

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes for cancer even as it prepares to be acquired by Bristol-Myers Squibb Co. (NYSE:BMY).

The deals complement Celgene's 2016 partnership with cancer metabolism play Agios Pharmaceuticals Inc. (NASDAQ:AGIO), and its acquisition of CAR T cell company Juno Therapeutics Inc. and in-licensing of a CAR T cell therapy from bluebird bio Inc. (NASDAQ:BLUE) last year...